Insmed disclosed that brensocatib (Brinsupri) failed a Phase 2b study in chronic rhinosinusitis without nasal polyps, ending a recent run of positive news and triggering a near‑term share price drop. The company said the trial showed no benefit at tested doses and will discontinue that development path while continuing other programs. Insmed announced it will add a new monoclonal antibody asset, INS1148, into the pipeline for Phase 2 development targeting respiratory and inflammatory diseases. Management characterized the negative result as a clear answer and emphasized continued focus on other late‑stage opportunities that support commercial forecasts. The episode highlights risk in label expansions for approved drugs and the importance of disease‑specific models for translational decisions. Investors will watch execution on the new acquisition and readouts from Insmed’s other respiratory programs.